What is Paradigm Biopharmaceuticals about?
Paradigm Biopharmaceuticals (ASX:PAR) is an Australian biotechnology company developing injectable pentosan polysulfate sodium (iPPS) for the treatment of osteoarthritis (OA). OA is a degenerative joint disease that affects millions of people worldwide, and there is currently no cure. Paradigm's operations are focused on the development and commercialisation of iPPS. The company is currently conducting Phase 3 clinical trials of iPPS for the treatment of knee OA, and it expects to submit regulatory applications for approval in 2024. Paradigm is also exploring the use of iPPS to treat other forms of OA, such as hip and shoulder OA.
Is Paradigm Biopharmaceuticals a public or private company?
How many people does Paradigm Biopharmaceuticals employ?
What sector is Paradigm Biopharmaceuticals in?
Where is the head office for Paradigm Biopharmaceuticals?
What year was Paradigm Biopharmaceuticals founded?
Where does Paradigm Biopharmaceuticals operate? Locations of Paradigm Biopharmaceuticals global operations
- Global view
- Melbourne, Australia
What are Paradigm Biopharmaceuticals’s services?
Overview of Paradigm Biopharmaceuticals offerings
Osteoarthritis: Paradigm Biopharmaceuticals is developing Zilosul® (iPPS) for the treatment of osteoarthritis, with Phase 3 trials underway.
Respiratory: Paradigm Biopharmaceuticals is developing Pentosan Polysulfate Sodium to target ARDS based on its multiple mechanisms of action outlined in preclinical studies.
Lysosomal Storage Diseases: Paradigm Biopharmaceuticals is developing Pentosan Polysulfate Sodium to help manage bone and joint manifestations, chronic pain, and physical disability, key clinical manifestations of MPS I which remain despite treatment with HSCT and ERT.
Who is in the Paradigm Biopharmaceuticals executive team?
Paradigm Biopharmaceuticals leadership team
- Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTCFounder, MD & Exec. Chairman
- Dr. Donna L. Skerrett M.D., MSChief Medical Officer and Exec. Director
- Mr. Justin CahillChief Financial Officer
- Dr. Ravi KrishnanChief Scientific Officer
- Mr. Simon WhiteDirector of Investor Relations
- Dr. Michael ImperialeGlobal Head of Drug Safety & MPS
- Ms. Beverley HuttmannCommercial Head
- Ms. Michelle CoffeyGlobal Head of Regulatory Affairs